FDA Peptide Update: Category 2 Removals Explained FDA issued its first warning letter to a dispenser (a medical spa) for violating the Drug Supply Chain Security Act (DSCSA), including failing to source products from authorized trading partners and FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures wkyc.com FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea